Tasly Pharmaceutical Group Co Ltd
SSE:600535

Watchlist Manager
Tasly Pharmaceutical Group Co Ltd Logo
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Watchlist
Price: 14.74 CNY 1.94% Market Closed
Market Cap: 22B CNY
Have any thoughts about
Tasly Pharmaceutical Group Co Ltd?
Write Note

Tasly Pharmaceutical Group Co Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tasly Pharmaceutical Group Co Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Total Liabilities
ÂĄ5.1B
CAGR 3-Years
15%
CAGR 5-Years
-18%
CAGR 10-Years
-4%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Liabilities
ÂĄ7.2B
CAGR 3-Years
35%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Liabilities
ÂĄ3.4B
CAGR 3-Years
11%
CAGR 5-Years
10%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Liabilities
ÂĄ5.6B
CAGR 3-Years
6%
CAGR 5-Years
15%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Liabilities
ÂĄ15B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Liabilities
ÂĄ1.3B
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tasly Pharmaceutical Group Co Ltd
Glance View

Market Cap
22B CNY
Industry
Pharmaceuticals

Tasly Pharmaceutical Group Co., Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The company is headquartered in Tianjin, Tianjin and currently employs 9,437 full-time employees. The company went IPO on 2002-08-23. The firm's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The firm's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The firm mainly distributes its products in the domestic market.

Intrinsic Value
19.8 CNY
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Tasly Pharmaceutical Group Co Ltd's Total Liabilities?
Total Liabilities
5.1B CNY

Based on the financial report for Jun 30, 2024, Tasly Pharmaceutical Group Co Ltd's Total Liabilities amounts to 5.1B CNY.

What is Tasly Pharmaceutical Group Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
-4%

Over the last year, the Total Liabilities growth was 1%. The average annual Total Liabilities growth rates for Tasly Pharmaceutical Group Co Ltd have been 15% over the past three years , -18% over the past five years , and -4% over the past ten years .

Back to Top